戈舍瑞林联合阿那曲唑作为一线内分泌方案治疗绝经前伴中、高危复发转移因素乳腺癌的临床研究  被引量:8

Anastrozole combined with goserelin in pre-menopausal patients with hormone dependent breast cancer inclined to recurrence and metastasis

在线阅读下载全文

作  者:陈德滇[1,2] 黄胜[1,2] 周绍强 陈文林[1,2] 杨庄青[1,2] 张季[1,2] 聂建云[1,2] 

机构地区:[1]昆明医学院第三附属医院 [2]云南省肿瘤医院乳腺治疗中心云南省乳腺癌临床研究中心,云南昆明650118

出  处:《中国癌症杂志》2011年第3期225-227,共3页China Oncology

摘  要:背景与目的:现已证实治疗绝经前乳腺癌患者,阿那曲唑疗效优于他莫昔芬,并有研究表明戈舍瑞林为安全有效的卵巢去势药物,然而两者联用作为乳腺癌内分泌治疗一线方案则鲜有报道。本研究旨在观察分析戈舍瑞林联合阿那曲唑作为绝经前伴中、高危复发转移因素的乳腺癌一线内分泌治疗临床疗效和预后。方法:分析本中心2002年至今应用戈舍瑞林联合阿那曲唑作为绝经前伴中、高危复发转移因素的68例乳腺癌患者一线内分泌治疗方案的疗效和预后;应用戈舍瑞林3.6 mg,每28 d皮下注射1次;阿那曲唑1 mg口服,每天1次;28 d为1个周期。所有患者按期评价疗效和不良反应。结果:68例患者中2例出现肿瘤复发转移,其余66例患者随访至今未出现肿瘤复发转移;中位治疗时间为3.6年,中位随访时间为48个月,无病生存率(disease-free survival,DFS)为97.1%,总生存率(overall survival,OS)为98.5%。结论:戈舍瑞林联合阿那曲唑治疗绝经前伴有中、高危复发转移因素乳腺癌疗效肯定,不良反应较轻,是一种有效的一线内分泌治疗药物。Background and purpose:In postmenopausal patients,aromatase inhibitors have shown signi?cantly more bene?ts than tamoxifen.Ovarian-function suppression(goserelin) is safe and useful for suppressing ovarian function in premenopausal patients.The use of aromatase inhibitors in combination with ovarian-function suppression is currently under investigation in the premenopausal state.This study analyzed the clinical characteristics,disease-free survival(DFS),and overall survival(OS) when combined with anastrozole and LHRH agonist,goserelin,as a first-line endocrine therapy for pre-menopausal patients with hormone dependent breast cancer who were also inclined to recurrence or metastasis.Methods:This study analyzed 68 patients with hormone dependent breast cancer who were inclined to recurrence or metastasis using goserelin,3.6 mg hypodermic injection every 28 days and anastrozole 1 mg were administered orally.Results:The median endocrine therapy time for these patients was 3.6 years and the median follow-up was 48 months.Two of all patients showed breast cancer metastasis,whereas the others were not.DFS was 97.1%,and OS was 98.5%.Conclusion:The combination of anastrozole and goserelin may be an effective first-line endocrine therapy for pre-menopausal patients with hormone dependent breast cancers that are inclined to recurrence and metastasis.

关 键 词:乳腺癌 内分泌治疗 阿那曲唑 芳香化酶抑制剂 戈舍瑞林 

分 类 号:R73[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象